SOURCE: P2D Bioscience

P2D Bioscience

June 22, 2011 11:06 ET

P2D Bioscience Awarded NIH Grant to Develop PD2007

CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Jun 22, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that it has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007's efficacy at inhibiting dopamine transport in multiple brain regions.

The major improvement of PD2007 over current dopamine transport inhibitors on the market (Adderall®, Concerta®) is its safety profile. Preclinical testing indicates that in addition to PD2007's efficacy, PD2007 demonstrates no abuse potential, which is a clear advantage over currently approved dopamine transport inhibitors which are Schedule II drugs of abuse. Further, PD2007 demonstrates no functionally significant cardiovascular effects on blood pressure and heart rate unlike currently approved dopamine transport inhibitors. Dr. Frank Zemlan, P2D Bioscience's CEO, predicts that a new dopamine transport inhibitor without the side effect burden of currently approved inhibitors could dominate the $3.5 billion market.

P2D Bioscience is currently raising private equity funding for PD2007 clinical safety and efficacy studies, as well as to support testing of P2D's proprietary TNF-alpha inhibitors.

About P2D Bioscience (P2D, Inc.)

P2D Bioscience is a privately held biopharmaceutical company focused on developing treatments for inflammatory and central nervous system diseases. P2D is developing first-in-class treatments for these disorders utilizing novel proprietary chemical compounds. For example, P2D's anti-inflammatory compounds are proprietary drugs that inhibit TNF-alpha synthesis or a "chemical switch," RAC/GTPase. These targets are critical components in the inflammatory pathway of several chronic disease such as chronic obstructive pulmonary disease (COPD) and asthma. Additional information about P2D products in development may be found at

Forward-Looking Statements

This press release contains forward looking-statements related to development of P2D's candidate drug products. Words such as, but not limited to, "believe", "could", "expect", "anticipate", "intend", "likely", "should", "suggest" and similar words identify forward-looking statements. These statements are not historical facts and are subject to risks and uncertainties that could cause actual results or the timing of specified events to differ materially from those set forth or implied herein including, without limitation, risks associated with preclinical and clinical development, regulatory approval, product commercialization, intellectual property claims and other risks related to P2D's activities.

Contact Information